The effects of add-on therapy of DPP4 inhibitor, Vildagliptin, on glucose control and diabetic complication in type 2 diabetes mellitus treated with insulin administration

The effects of add-on therapy of DPP4 inhibitor, Vildagliptin, on glucose control and diabetic complication in type 2 diabetes mellitus treated with insulin administration - The effects of combination therapy of Vildagliptin and Insulin on diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010176

Enrollment

400

Registered

2013-03-06

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Vildagliptin, 50-100mg, once or twice/day, 5 years no Vildagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus with insulin therapy

Exclusion criteria

Exclusion criteria: type 1 diabetes mellitus, severe liver injury, heart failure, pancreatitis, ileus

Design outcomes

Primary

Measure	Time frame
Plasma glucose, HbA1c, diabetic retinopathy, diabetic nephropathy, cardiovascular disease, cerebral infarction, fracture, cancer	—

Countries

Japan

Contacts

Public ContactIppei Kanazawa

Shimane University Faculty of Medicine Endocrinology and Metabolism

ippei.k@med.shimane-u.ac.jp0853-20-2183

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026